Addrenex acquires promising narcolepsy therapy from SK Holdings
This article was originally published in Scrip
Executive Summary
Addrenex Pharmaceuticals has acquired global rights outside east Asian markets to SK Holdings' ADX-N05, an early development-stage molecule with potential in narcolepsy and other CNS indications.